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Introduction
The past year demonstrated how developing pharmacological solutions forbetter ways of insulin substitution and making those drugs commercially available
for patients with all forms of diabetes are becoming more and more complex issues
worldwide in the light of increasing patient numbers and rising health-care costs.
Meanwhile, the two first rapid-acting analogs are celebrating their 20th (insulin lispro
(1)) and 15th (insulin aspart (2)) anniversaries of commercial approval. The discussion
on the long-term safety concerns of insulin analogs has quieted down considerably and
only further reassuring data regarding mitogenicity have become available lately (3).
In 2013 the U.S. Food and Drug Administration (FDA) had requested additional
cardiovascular data from a dedicated cardiovascular outcomes trial before the review
of the New Drug Application for the long-acting insulin degludec could be completed.
Degludec had received marketing authorization valid throughout the European Union
(EU) and other countries already early 2013. In September 2015, the FDA approved
Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin
aspart injection) after reassuring data from the DEVOTE trial. But marketing approval
does not necessarily translate into reimbursement. After degludec was denied a ben-
efit in the health technology assessment of the German Institute for Quality and
Efficiency in Health Care (IQWIG) as part of the so-called AMNOG process (Gesetz
zur Neuordnungsgesetz des Arzneimittelmarkt-‘‘Pharmaceuticals Market Reorganisa-
tion Act’’) for new drug entities in Germany, the German authorities were unwilling to
accept a price premium over other long-acting insulins because the benefit was con-
sidered marginal. Hence Novo Nordisk took the difficult decision to pull degludec
from the German market in January 2016 because other markets (e.g., China) set
their price on the basis of Germany. As a consequence, 40,000 German patients
on degludec—many of the claiming significant improvements over their previous
therapy - had to be transferred to another insulin regimen. In contrast, Toujeo, the
U300 insulin glargine approved by the European Agency for the Evaluation of
Medicinal Products (EMEA) and the Food and Drug Administration (FDA) in 2015 is
not considered a new drug entity and therefore had not to undergo an IQWIG as-
sessment or the AMNOG process and is currently reimbursed in Germany and many
other countries. The ultra-fast-acting insulins, such as fast-acting insulin aspart
(FiAsp, i.e., NN-1218 or ultra-fast-acting insulin aspart, Novo Nordisk) and Bio-
Chaperone Lispro remain on the horizon. However, the communication of the results
of clinical studies so far has been dominated by congress presentations and company
announcements and the peer-reviewed evidence to date remains scarce. In the year one
after the first biosimilar insulin (BioIns) got market approval in the EU and the United
States, one has to acknowledge that not too much has happened from a general per-
spective. This version of insulin glargine developed by Eli Lilly and Boehringer
Ingelheim (Abasaglar in the EU and Basaglar in the United States) is not on the market
in the United States until now (summer 2016, but will come shortly) and has gained
significant market share in some countries in the EU only. In such countries the
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decrease in prices observed is quite different, with a maximum of up to 30%. In March
of 2016 the Holy Grail promise of a ‘‘smart’’ insulin, or glucose-responsive insulin,
was the focus of a joint investment from the Juvenile Diabetes Research Foundation
( JDRF) and Sanofi. The $4.6 million in funding over three years will support early
research from four researchers developing new and discrete approaches to glucose-
responsive insulin. JDRF has prioritized this area of research for several years now,
and more collaborations may be announced in the next few months.
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Background
The aim of this trial was to compare the efficacy and safety
of the new insulin glargine 300 U/mL (Gla-300) versus the
original insulin glargine 100 U/mL (Gla-100) in Japanese
adult subjects with type 1 diabetes.
Methods
A multicenter, open-label, phase 3 trial over six months.
Two-hundred and forty-three adults with type 1 diabetes on
basal/bolus insulin therapy were randomized to Gla-300 or
Gla-100 in combination with prestudy meal-time insulin.
Basal insulin was titrated to achieve fasting plasma glucose
between 4.4 to 7.2 mmol/L.
Results
Glycemic control (HbA1c) over the six month study period
was comparable between Gla-300 and Gla-100 [least squares
mean difference 0.13% (95% CI - 0.03 to 0.29)], demon-
strating noninferiority. The annualized rate of confirmed
(self-measured plasma glucose £ 3.9 mmol/L) or severe hy-
poglycemia was lower with Gla-300 than with Gla-100 at
night time (rate ratio 0.66 [95% CI 0.48–0.92]) and at any
time of the day (rate ratio 0.80 [95% CI 0.65–0.98]); the
difference being most marked during the first eight weeks of
the study. At six months, the daily basal insulin dose had
increased in both groups to 0.35 U/kg with Gla-300 and
0.29 U/kg with Gla-100. Body weight change was less pro-
nounced with Gla-300 than with Gla-100 [least square mean
difference - 0.6 kg (95% CI - 1.1 to - 0.0); P = 0.035. Ad-
verse events were comparable between the groups.
Conclusions
In Japanese adults with type 1 diabetes on multiple injec-
tion therapy, basal insulin supplementation with Gla-300
attained comparable glycemic control (HbA1c) as compared
with Gla-100, with significantly less daily hypoglycemia and,
in particular, less nocturnal hypoglycemia.
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Background
The aim of this study was to compare the long-term effi-
cacy and safety of insulin glargine 300U/mL (Gla-300) with
glargine 100 U/mL (Gla-100) in adults with type 2 diabetes
using combination therapy with basal insulin and oral anti-
hyperglycemic drugs (OADs).
Methods
Multicentre, open-label, parallel group trial, where adults
with type 2 diabetes were randomized to once-daily injections
of Gla-300 or Gla-100 together with OADs (with the exception
of sulphonylureas) for six months, and for an additional six
month extension period.
Results
Seventy-eight percent of the participants in the Gla-300
group and 77% in the Gla-100 group completed the full
12 month study period. The reduction in HbA1c was main-
tained over 12 months in both groups; the least squares mean
change from basal being - 0.55% with Gla-300 and - 0.50%
with Gla-100 (least squares mean difference - 0.06% [95%
CI - 0.22–0.10]). The annualized rate of nocturnal confirmed
(self-measured plasma glucose £ 3.9 mmol/L) or severe hy-
poglycemia was significantly lower with Gla-300 than
with Gla-100 (rate ratio 0.63 [95% CI 0.42–0.96]; P = 0.031),
and the percentage of participants experiencing ‡ 1 event
was lower with Gla-300 (relative risk 0.84 [95% CI 0.71–
0.99]). Weight gain was less pronounced with Gla-300 than
with Gla-100 (least squares mean difference - 0.7 kg (95%
CI - 1.3 to - 0.2); P = 0.009). Adverse event patterns were
similar in the two groups.
Conclusions
In adults with type 2 diabetes using combination therapy
with basal insulin plus OADs, the improvement in glycemic
control is maintained over 12 months with Gla-300 and Gla-
100, but with less nocturnal hypoglycemia with Gla-300.
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Background
The aim of this extension study was to evaluate the long-
term efficacy and safety of insulin degludec in adults with type
2 diabetes, using basal/bolus insulin therapy with or without
the addition of metformin and/or pioglitazone. Comparison
was made with insulin glargine 100U/mL as basal insulin.
Methods
In the original 52 week trial, 1006 adults with type 2 dia-
betes previously treated with any kind of insulin regimen,
with or without metformin and/or pioglitazone, were ran-
domized (3:1) to basal insulin supplementation with once-
daily insulin degludec (IDeg) or insulin glargine (IGla);
all together with mealtime insulin aspart. Basal insulin
doses were titrated to attain prebreakfast plasma glucose
between 3.9 to 4.9 mmol/L. Seventy-five percent of the
participants in the IDeg group and 76% in the IGla group
continued their assigned treatment for an additional 26
week extension period.
Results
After 78 weeks, improvement in glycemic control (HbA1c)
was sustained and comparable in both groups. The overall rate
of hypoglycemia (defined as plasma glucose < 3.1 mmol/L or
severe hypoglycemia) was 24% lower (P = 0.011), and the rate
of nocturnal hypoglycemia 31% lower (P = 0.016), in the IDeg
group. Total insulin doses and rates of adverse events were
comparable in the two groups.
Conclusions
Throughout 18 months of basal insulin supplementation
with insulin degludec in combination with mealtime insulin
aspart – oral antidiabetic drugs (OADs), improvement in
glycemic control was maintained in the same way as with
insulin glargine, but with less risks of overall and nocturnal
hypoglycemia.
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Background
The aim of this study was to compare the efficacy and
safety of insulin glargine 300 U/mL (Gla-300) with other
basal insulins (NPH, detemir, premixed insulins, and deglu-
dec) in adults with type 2 diabetes. In the absence of direct
head-to-head comparative trials, this was done by a com-
prehensive literature review and network meta-analysis to
estimate comparative effects of multiple interventions using
indirect evidence.
Methods
Network meta-analysis of randomized clinical trials of
basal insulin therapies in subjects with type 2 diabetes,
identified by a systematic literature review of several
databases. Outcome measures included changes in glycemic
control (HbA1c) and body-weight, and rates of nocturnal and
documented symptomatic hypoglycemia.
Results
Altogether 41 studies were included in the network meta-
analysis. Change in HbA1c was comparable between Gla-
300 and all comparator basal insulins. Change in body weight
was similar between Gla-300 and detemir and NPH and
degludec, respectively, but lower compared with premixed
insulin ( - 1.83 kg [95% Credible Interval (CrI) - 2.85 to
- 0.75]). Rate of nocturnal hypoglycemia was lower with
Gla-300 versus NPH (risk ratio 0.18 [95% CrI 0.05–0.55])
and premixed insulin (risk ratio 0.36 [95% CrI 0.14–0.94]),
but not significantly different from that with detemir or de-
gludec. Rates of documented symptomatic hypoglycemia
were not significantly different between Gla-300 and NPH,
detemir, or degludec.
Conclusions
The findings of this network meta-analysis suggest that
basal insulin supplementation in type 2 diabetes with Gla-300
is associated with less risk of nocturnal hypoglycemia com-
pared with NPH and premixed insulin, with glycemic control
being comparable to all the comparator basal insulins.
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Background
Insulin degludec/insulin aspart (IDegAsp) is a premixed
coformulation of insulin degludec and insulin aspart (70/30
ratio). The aim of this study was to assess the long-term safety
and efficacy of IDeg/Asp once daily (at main meal) in com-
bination with insulin aspart at remaining meal times versus a
conventional multiple daily injection therapy with insulin de-
temir (IDet; once or twice daily) together with insulin aspart
(IAsp) at mealtimes in adult subjects with type 1 diabetes.
Methods
Multicenter, parallel-group, open-label, phase 3 trial, where
adult subjects with type 1 diabetes (n = 548) were randomized
(2:1) to IDegAsp + IAsp or IDet + IAsp for 26 weeks followed
by a 26 week extension period. Insulins were titrated to achieve
plasma glucose < 5 mmol/L before breakfast (IDegAsp- and
IDet-doses) and before meals (IAsp-doses).
Results
At week 52, the mean HbA1c decrease from baseline was
- 0.7% with IDeg/Asp + IAsp and - 0.6% with IDet + IAsp,
to a final mean HbA1c of 7.6% and 7.7%, respectively. The
rate of overall confirmed hypoglycemia (plasma glucose
< 3.1 mmol/L) was comparable with both insulin regimens
(31.8 episodes/patient-years of exposure [PYE] with IDegAsp +
IAsp and 36.7 episodes/PYE with IDet + IAsp), whereas the
rate of nocturnal confirmed hypoglycemia was significantly
lower with IDeg/Asp + IAsp (3.1 episodes/PYE) than with
IDet + IAsp (5.4 episodes/PYE); (P < 0.05). The mean total
daily dose of insulin was smaller with IDeg/IAsp + IAsp than
with IDet + IAsp; the ratio between the groups being 0.87
(95% CI 0.79–0.95; P = 0.0026). Rates of adverse events were
comparable.
Conclusions
Once-daily administration of the IDeg/Asp coformulation
together with IAsp at remaining meals improved glycemic
control equally good as a standard multiple daily injections
(MDI)-regimen with IDet plus meal IAsp, but with signifi-
cantly less risk of nocturnal confirmed hypoglycemia in
adults with type 1 diabetes.
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Background
The aim of this study was to assess the pharmacokinetic and
pharmacodynamics characteristics of insulin degludec/insulin
aspart (IDeg/Asp) in children (age 6 to 11 years), adolescents
(12 to 17), and adults (18 to 65) with type 1 diabetes.
Methods
Single-center, open-label, single-dose trial. The partici-
pants (38 in total) were given a single subcutaneous injection
of IDeg/Asp (0.5 U/kg) immediately before a standardized
liquid meal adjusted for body weight. Plasma glucose (PG)
and insulin concentrations (IDeg and IAsp) were followed up
to 57 hours after insulin administration.
Results
The mean postprandial PG profiles after the standardized
meal test - including the PG lowering effect, the maximum
PG excursion, and the maximum PG concentration—were
comparable for all age groups. Estimated ratios (ER) for total
exposure area under the curve (AUC) IAsp, 0–12h, SD) and
maximum concentration (Cmax, IAsp, SD) of IAsp were 1.69
(95% CI: 1.02–2.80) and 1.66 (95% CI: 1.10–2.51), respec-
tively, for children/adults, and 1.14 (95% CI: 0.76–1.69) and
1.16 (95% CI: 0.84–1.61), respectively, for adolescents/
adults. ERs for total exposure (AUCIDeg, 0-N, SD) and maxi-
mum concentration (Cmax, IDeg, SD) of IDeg were 1.42 (95%
CI: 0.94–2.16) and 1.38 (95% CI: 1.09–1.76), respectively
for children/adults, and 1.23 (95% CI: 0.96–1.58) and 1.16
(95% CI: 0.95–1.42), respectively, for adolescents/adults.
Conclusions
The rapid onset of the prandial coverage of the IAsp
component and the protracted pharmacokinetic profile of the
IDeg component of IDeg/Asp were similar in children and
adolescents, as compared with adults. Exposure to both IAsp
and IDeg was higher in children than in adults, but there were
no differences in the PG lowering effect. Accordingly, the
IDeg/IAsp-coformulation may be a treatment alternative in
children and adolescents with type 1 diabetes.
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Background
The influence of ultra-long-acting insulins on hypogly-
cemia counter-regulation and hypoglycemia risk is not very
well evaluated. The aim of this study was to assess blood
glucose and counter-regulatory hormonal responses to
aerobic high-intensity interval exercise (HIIE) and mod-
erate continuous exercise (CON) matched for load and
duration in subjects with type 1 diabetes using insulin de-
gludec as basal insulin.
Methods
Seven trained males with type 1 diabetes first performed a
maximal incremental exercise test and then 30 min HIIE and
CON tests at three different mean intensities; each test being
separated by one week. Prior to the exercise tests, the par-
ticipants had been adjusted to basal insulin supplementation
with insulin degludec once daily (evening). Before exercise,
standardized meals were given, and the short-acting insulin
dose was reduced by 25% to 75%, depending on the exercise
intensity. Blood glucose (BG) and counter-regulatory hor-
monal responses together with blood lactate, heart rate, and
pulmonary gas exchange variables were measured during the
tests, and glucose control over 24 h after exercise was reg-
istered by a continuous glucose monitoring system.
Results
Compared to CON, the lowering of BG during HIIE was
significantly smaller at the intermediate exercise intensity,
and tended to be smaller during the other two intensities. No
differences between HIIE and CON were seen with regard to
counter-regulatory hormone responses, carbohydrate utili-
zation or postexercise glucose control. No hypoglycemic
events (glucose < 3.3 mmol/L) were observed during or after
the various tests. Increases in blood lactate and respiratory
exchange ratios were significantly higher during HIIE than
during CON at the two lower exercise intensities, but not at
the highest.
Conclusions
HIIE and CON was performed without hypoglycemic
events during or after exercise in subjects with type 1 diabetes
using insulin degludec as basal insulin and applying stan-
dardized carbohydrate intake and reductions of bolus insulin
doses before the tests. While both exercise modes were
matched for mean load and duration, HIIE resulted in less
pronounced BG decrease compared to CON, although higher
peak workloads were applied in HIIE. Therefore, HIIE and
CON could both be safely recommended.
Similar risk of exercise-related hypoglycaemia
for insulin degludec to that for insulin glargine
in patients with type 1 diabetes: a randomized
cross-over trial
Heise T1, Bain SC 2, Bracken RM 2, Zijlstra E1, Nosek L1,
Stender-Petersen K 3, Rabøl R 3, Rowe E 4, Haahr HL 3
1Profil, Neuss, Germany; 2Diabetes and Endocrinology
Department, Swansea University, UK; 3Novo Nordisk A/S,
Søborg, Denmark; 4Novo Nordisk Inc., Plainsboro, NJ
Diabetes Obes Metab 2016; 18: 196–199
Background
The aim of this study was to compare changes in blood
glucose (BG) and susceptibility to hypoglycemia during and
after exercise in subjects with type 1 diabetes using insulin
degludec (IDeg) or insulin glargine (IGla) as basal insulin.
Methods
Randomized, open-label, two-period, crossover trial in 40
subjects with type 1 diabetes. Following individual titra-
tion and steady-state dosing with each of the two basal in-
sulins in random order, the subjects performed a 30 min
moderate-intensity cycle ergometer exercise test (65% peak
rate of oxygen uptake). BG, counter-regulatory hormones,
and hypoglycemic events (plasma glucose £ 3.1 mmol/L
or requiring assistance) were recorded during and for 24 h
after exercise.
Results
BG lowering during exercise was comparable with IDeg
and IGla [estimated treatment difference for maximum BG
decrease 0.14 mmol/L (95% CI - 0.15 to 0.42; P = 0.34)], as
was the mean BG [estimated treatment difference - 0.16 mmol/
L (95% CI - 0.36 to 0.05; P = 0.13)]. No hypoglycemic event
was registered during the exercise test. Postexercise mean BG
and counter-regulatory hormonal responses were similar with
both insulins. Likewise, the number of hypoglycemic episodes
within 24 h after starting exercise was comparable; 18 events in
13 subjects with IDeg, and 23 events in 15 subjects with IGla.
Conclusions
In subjects with type 1 diabetes using basal/bolus insulin
treatment, the risk of hypoglycemia provoked by moderate-
intensity exercise is small and similar for IDeg and IGla.
INSULIN PEGLISPRO: END OF THE STORY
Randomized clinical trial comparing basal insulin
lispro and insulin glargine in patients with type 2
diabetes previously treated with basal insulin:
IMAGINE 5
Buse JB1, Rodbard HW 2, Trescoli Serrano C 3, Luo J 4,
Ivanyi T 4, Bue-Valleskey J 4, Hartman ML 4, Carrey MA 5,
Chang AM 4; for the IMAGINE 5 Investigators
1University of North Carolina School of Medicine, Chapel Hill,
N; 2Endocrine and Metabolic Consultants, Rockville, MD;
3Hospital de la Ribera, Valencia, Spain; 4Eli Lilly and Com-
pany, Indianapolis, IN; 5inVentiv Health Clinical, Blue Bell, PA
Diabetes Care 2016; 39: 92–100
Background
The aim of this study was to assess the long-term safety
and efficacy of the ultra-long-acting basal insulin peglispro
(BIL) compared with insulin glargine in subjects with type 2
diabetes previously treated with basal insulin alone or in
combination with oral antihyperhyperglycemic drugs.
Methods
Fifty-two week, phase 3, open-label, treat-to-target trial
where subjects with a mean HbA1c of 7.42% (57.6 mmol/
mol) were randomized to basal insulin supplementation with
BIL (n = 307) or glargine (n = 159). Primary outcome was
change from baseline HbA1c from baseline.
Results
At 26 weeks, the lowering of HbA1c was greater with BIL
( - 0.82% [ - 8.9 mmol/mol]) than with glargine ( - 0.29%
[ - 3.2 mmol/mol]); the least square mean difference being
- 0.52%, 95% CI: - 0.67 to - 0.38 ( - 5.7 mmol/mol, 95%
CI: - 7.3 to - 4.2); P < 0.001. At 52 weeks, the greater re-
duction in HbA1c with BIL was sustained, and more subjects
in the BIL group achieved HbA1c less than 7% (53 mmol/L)
at 26 and 52 weeks (P < 0.001 at both time points). At both 26
and 52 weeks, BIL subjects experienced 60% less nocturnal
hypoglycemia (P £ 0.001), more subjects achieved the treat-
ment goal (HbA1c < 7%; 53 mmol/mol) without nocturnal
hypoglycemia (P < 0.001), and glucose variability was lower
(P < 0.01), as compared with glargine. At 52 weeks, total rate
of hypoglycemia was lower with BIL than with glargine
(P < 0.03). At weeks 26 and 52, insulin dose (P < 0.001) was
higher with BIL than with glargine. Triglycerides and amino-
transferases were also significantly higher with BIL (P < 0.05).
Liver fat content (investigated in a subset of 162 subjects), was
increased from baseline with BIL versus glargine (P < 0.001),
with unchanged levels between week 26 and 52.
Conclusions
BIL therapy resulted in greater improvement in glycemic
control versus glargine, with less nocturnal and total rates of
hypoglycemia and lower glucose variability, and lead to in-
creased triglycerides, aminotransferases, and liver fat content.
Basal insulin peglispro versus insulin glargine
in insulin-naı̈ve type 2 diabetes: IMAGINE
2 randomized trial
Davies MJ1, Russell-Jones D 2, Selam J-L 3, Bailey TS 4,
Kerényi Z 5, Luo J 6, Bue-Valleskey J 6, Iványi T 7,
Hartman ML 6, Jacobson JG 6, Jacober SJ 6; for the
IMAGINE 2 Study Investigators
1Department of Health Sciences, Diabetes Research Centre,
University of Leicester, Leicester, UK; 2Department of En-
docrinology and Diabetes, Royal Surrey Country Hospital,
Guildford, UK; 3Diabetes Research Center, Tustin, CA;
4AMCR Institute, Escondido, CA; 5Csepel Health Service,
Budapest, Hungary; 6Eli Lilly and Company, Indianapolis,
IN; 7Eli Lilly and Company, Budapest, Hungary
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Background
The aim of this study was to compare the long-term safety
and efficacy of basal insulin peglispro versus insulin glargine
as add-on to oral hypoglycemic drugs in insulin-naı̈ve, type 2
diabetic subjects.
Methods
Phase 3, multi-national, double-blind, trial. One thousand
five hundred and thirty-eight subjects were randomized (2:1)
to treatment with peglispro or glargine for 52 weeks, with an
additional 26 week extension period (n = 920). The primary
outcome was noninferiority of peglispro to glargine in terms
of HbA1c reduction (margin 0.4%). There were also several
gated secondary outcomes with statistical multiplicity ad-
justments regarding glycemic control and safety. Liver fat
content was assessed by magnetic resonance imaging (MRI)
in a subset of 168 subjects.
Results
Compared with glargine, peglispro treatment resulted
in a statistically significant greater reduction of HbA1c
(P < 0.001), but within the prespecified noninferiority margin
(least squares mean difference ( - 0.29%, 95% CI: - 0.40 to
- 0.19). Peglispro subjects experienced lower rate of noc-
turnal hypoglycemia (relative rate 0.74 [95% CI: 0.60–0.91];
P = 0.005), and more subjects achieved HbA1c < 7% (odds
ratio (OR) 1.97 [95% CI: 1.57–2.47]; P < 0.001) and HbA1c
< 7% without nocturnal hypoglycemia (OR 2.15 [95% CI:
1.60–2.89]; P < 0.001). Incidence of total hypoglycemia and
fasting serum glucose were comparable between the two
groups. At 52 weeks, subjects on peglispro had higher tri-
glyceride (1.9 vs. 1.7 mmol/L, alanine transaminase (34 vs.
27 IU/L), and aspartate transaminase (27 vs. 24 IU/L) levels.
At 52 weeks, least square mean liver fat content had not
changed from basal values in peglispro subjects but had de-
creased by 3.1% in glargine subjects (difference 2.6% [95% CI:
0.9–4.2]; P = 0.002). Adverse injection site reactions were more
common in the peglispro group (3.5% vs. 0.6%; P < 0.001).
Conclusions
Compared to glargine, treatment with peglispro lead to
a statistically significant greater reduction in HbA1c, more
subjects attaining HbA1c target, lower incidence of noctur-
nal hypoglycemia, comparable rates of total hypoglycemia,
higher triglyceride and aminotransferase levels, and more
frequent injection site reactions.
Comment
In the last years, we have reviewed comprehensively
about the two newest ultra-long-acting insulin anlogs on
the market; glargine 300 U/mL (Tuejo) from Sanofi and
degludec (Tresiba) from Novo Nordisk. As the U.S.
Food and Drug Administration (FDA) in September
2015 approved Tresiba (and the premixed combination
of degludec and the rapid-acting analog aspart; Ryzodeg
70/30) after an interim analysis of a dedicated cardio-
vascular outcomes trial (DEVOTE), both analogs are
now available in Europe and in the United States.
This year, we present data from extension studies of
previously-published phase 3 trials with both analogs,
which show that improvements in glycemic control
(HbA1c) are maintained over longer periods of time.
Moreover, reduced risk of hypoglycemia – and espe-
cially nocturnal hypoglycemia – seems to be a consistent
finding also after longer follow ups, and no alarming
safety issues have been observed. Unfortunately, there
is still no head-to-head comparison between glargine
300 U/ml and degludec. By using data from several ran-
domized, controlled trials in a network meta-analysis,
Freemantle and coworkers indirectly compared the effec-
tiveness of different basal insulins, including Tuejo and
Tresiba. According to their analysis, there were no
apparent differences with regard to glycemic control or
risk of hypoglycemia between the two new analogs.
However, randomized, controlled, treat-to-target trials
directly comparing the ultra-long-acting analogs in both
type 1 and type 2 diabetes are necessary to make any
firm conclusions and are much awaited.
As mentioned, Novo Nordisk has also developed a
soluble coformulation consisting of 70% degludec and
30% aspart (Ryzodeg). Previous studies have demon-
strated that this combination provides both the stable
and protracted glucose-lowering effect of degludec and
the rapid prandial effect of aspart, and that there is a
clear dose-response relationship for both components
(4). In clinical testing, a marked improvement in glucose
control together with notable reductions in rates of total
and nocturnal hypoglycemia compared with biphasic
insulin aspart have also been shown in subjects with type
2 diabetes (5). The presently referenced trials, suggest
that Ryzodeg may also be used as part of a multiple daily
injection treatment regimen in both young and adult
subjects with type 1 diabetes. The advantages include
fewer injections and, according to the results of Hirsch
et al.’s study, less risk of hypoglycemia. It should be
borne in mind, however, that fixed dosing limits the
possibility of adjusting prandial insulin in relation to
meal demands, planned physical activity etc. In this
regard, the influence of ultra-long-acting insulin analogs
on hypoglycemia risk during or after exercise is a very
important clinical question. In both the two referenced
studies, the rapid-acting, prandial insulin dose before
exercise was reduced in relation to the work inten-
sity, according to therapy recommendations (6). In the
study by Moser and coworker, no hypoglycemia event
was recorded during or within 24 h after high-intensity
interval exercise or moderate continuous exercise
matched for work load and duration in subjects with
type 1 diabetes using degludec. Notably, however, the
mean blood glucose level before exercise was rather high
(about 11–13 mmol/L), i.e., with a rather large buffer
zone against hypoglycemia. In the study by Heise et al.,
hypoglycemia was registered postexercise in about
one-third of the participants in both the degludec group
and the glargine group, with most of the events occur-
ring during the night. While no information was given
regarding their general propensity for hypoglycemia,
this frequency of exercise-associated hypoglycemia ap-
pears rather high. Conceivably, more data regarding the
optimum insulin adjustments in conjunction with exer-
cise in subjects using ultra-long-acting insulin analogs
are needed.
In previous Yearbooks we have also commented ex-
tensively on another new ultra-long-acting basal insu-
lin analog, namely insulin peglispro, in development
by Lilly. Early trials with this analog with a more
hepato-preferential mode of action showed promising
results with regard to glycemic parameters, with even
better improvements of HbA1c and lower frequency
of nocturnal hypoglycemia as compared to insulin
glargine; findings that now have been corroborated in
the presently-referenced studies of longer duration.
However, elevations of triglycerides, liver enzymes
and liver fat content have been observed in parallel,
which may be the consequence of reduced peripheral
action of peglispro and thereby increased fatty acid
delivery to the liver. Based on this potentially delete-
rious side effect, Lilly in December 2015 announced
that the development program of peglispro has been
terminated.
BIOSIMILAR INSULIN
Comparison of the pharmacokinetics and pharma-
codynamics of LY2963016 insulin glargine and
European Union- and U.S.-approved versions of
Lantus insulin glargine in healthy subjects: three
randomized euglycemic clamp studies
Linnebjerg H1, Chen Quin Lam E 2, Seger ME1,
Coutant D1, Chua L 2, Lan Chong C 2, Ferreira MM 3,
Soon D 2, Zhang X1
1Eli Lilly and Company, Indianapolis, IN; 2Lilly-NUS
Centre for Clinical Pharmacology, Singapore; 3PAREXEL
International Bloemfontein Early Phase Unit, Bloemfontein,
South Africa
Diabetes Care 2015; 38: 2226–2230
Background
The insulin glargine products LY2963016 (LY IGlar)
and Lantus (IGlar) are manufactured by distinct processes
but they have an identical primary structure. Three studies
evaluated the pharmacokinetic (PK) and pharmacodynamic
(PD) similarity of both of these glargines (one glargine was
studied in two versions: one approved in the EU and the other
approved in the United States).
Methods
Three single-site, randomized, double-blind, two-treatment,
four period, crossover, euglycemic glucose clamp studies
were conducted. In each study, healthy subjects received
subcutaneous (SC) injections of 0.5 units/kg of the insulin
glargines on two occasions each, following a randomized
sequence. PD was assessed by a euglycemic glucose clamp
lasting up to 24 h.
Results
A total of 211 subjects participated in the three studies. The
PK (area under the curve; maximum observed concentration)
and PD (maximum glucose infusion rate; total glucose in-
fusion during the clamp) were observed to be similar between
LY IGlar and IGlar. The ratios of geometric means ranged
from 0.90 to 0.95 for PK parameters and from 0.91 to 0.99 for
PD parameters across the three studies. In all cases, the 90%
confidence intervals relating to the ratios of the geometric
means were totally contained within the prespecified accep-
tance limits of 0.80–1.25. Adverse events were observed to
be similar between the treatments.
Conclusions
In healthy subjects the PK and PD properties of LY IGlar
and IGlar were similar after single 0.5 units/kg s.c. doses,
contributing to the totality of evidence supporting similarity
of these products.
Comment
The PK and PD properties of the first approved BioIns
were studied in three glucose clamp studies with healthy
subjects and the main results obtained with a high insulin
dose (0.5 U/kg) were presented in this summary publi-
cation. In two comments the performance of these
studies and the interpretation were challenged (20,21).
Nevertheless, the PK and PD data presented make clear
that this biosimilar insulin glargine is quite similar to the
originator insulin. However, the variability of the indi-
vidual responses observed (see the large error bars) also
highlights the magnitude to which these differ.
Efficacy and safety of LY2963016 insulin glargine
compared with insulin glargine (Lantus) in
patients with type 1 diabetes in a randomized
controlled trial: the ELEMENT 1 study
Blevins TC1, Dahl D 2, Rosenstock J 3, Ilag L 4,
Huster W 4, Zielonka J 4, Pollom R 4, Prince M 4
1Texas Diabetes & Endocrinology, Austin, TX; 2Gemein-
schaftspraxis für Innere Medizin und Diabetologie, Ham-
burg, Germany; 3Dallas Diabetes and Endocrine Center
at Medical City, Dallas, TX; 4Eli Lilly and Company, In-
dianapolis, IN
Diabetes, Obesity and Metabolism 2015; 17: 726–733.
Background
The aim of this study was to compare the efficacy and
safety of LY2963016 insulin glargine (LY IGlar) and the
originator insulin (insulin glargine; IGlar) in patients with
type 1 diabetes (T1D).
Methods
In this phase III, randomized, open-label, 52-week study
535 patients with T1D were enrolled (HbA1c £ 11%).
These are treated with multiple daily injections, i.e., basal
insulin (once daily) and bolus insulin. Patients were ran-
domized to receive once-daily LY IGlar (n = 268) or IGlar
(n = 267).
Results
Both treatment groups had similar and significant
(P < 0.001) within-group decreases in mean HbA1c values
from baseline. LY IGlar met the noninferiority criteria
compared with IGlar for change in HbA1c from baseline to
24 weeks ( - 0.35% vs. - 0.46%, least squares mean differ-
ence 0.108% [95% CI - 0.002 to 0.219], P > 0.05). There
were no significant treatment differences in other efficacy
measures, including proportion of patients reaching HbA1c
< 7%, daily mean blood glucose, and insulin dose at 24 and
52 weeks. At 52 weeks, similar findings were observed be-
tween LY IGlar and IGlar for safety outcomes, including
adverse events, allergic reactions, hypoglycemia, weight
change, and insulin antibodies.
Conclusion
Both insulin glargines, when used in combination with
mealtime insulin lispro, provided effective and similar glu-
cose control and similar safety profiles.
Comment
Eli Lilly and Boehringer Ingelheim performed two large
clinical trials to get market approval in the United States
(these studies would not have been required for market
approval in the European Union). They named these
studies ELEMENT 1 and ELEMENT 2, in relation to the
patient group studied. In this study with patients with
type 1 diabetes no relevant differences were observed
in clinical endpoints (metabolic control and frequency
of hypoglycemic events) and side effects at the end of
the study. However, after 12 weeks significant higher
HbA1c values were observed with the BioIns, indicating
that the treating physicians in this open-label study were
somewhat reluctant to adjust the insulin dose as rapidly
as they did with the originator insulin. In combination
with the PK/PD data, the study results indicate that this
BioIns can be used like the originator insulin.
Similar efficacy and safety of LY2963016 insulin
glargine and insulin glargine (Lantus) in patients
with type 2 diabetes who were insulin-naı̈ve
or previously treated with insulin glargine:
a randomized, double-blind controlled trial (the
ELEMENT 2 study)
Rosenstock J1, Hollander P 2, Bhargava A 3, Ilag LL 4,
Pollom RK 4, Zielonka JS 4, Huster WJ 4, Prince MJ 4
1Dallas Diabetes and Endocrine Center at Medical City,
Dallas, TX; 2Baylor Endocrine Center, Dallas, TX; 3Iowa
Diabetes and Endocrinology Research Center, Des Moines,
IA, USA; 4Eli Lilly and Company, Indianapolis, IN
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Background
The aim of this study was to compare the efficacy and
safety of LY2963016 insulin glargine (LY IGlar) and the
reference product (Lantus) insulin glargine (IGlar) in com-
bination with oral antihyperglycaemic medications (OADs)
in patients with type 2 diabetes (T2D).
Methods
This phase 3, randomized, double-blind, 24-week study
enrolled patients with T2D who were insulin-naı̈ve (HbA1c
‡ 7 and £ 11.0%) or previously treated with a basal insulin
(HbA1c £ 11%) and treated with ‡ 2 OADs. Patients were
randomized to receive once-daily LY IGlar (n = 376) or IGlar
(n = 380) for 24 weeks.
Results
Both treatment groups had similar and significant (P < 0.001)
within-group decreases in mean HbA1c values from baseline.
LY IGlar met noninferiority criteria compared with IGlar for
change in HbA1c from baseline ( - 1.29% vs. - 1.34%; re-
spectively). The mean difference in HbA1c was 0.052% (95%
CI - 0.070 to 0.175; P > 0.05). There were no significant dif-
ferences in fasting plasma glucose, proportion of patients
reaching HbA1c < 7%, or insulin dose at 24 weeks. Also adverse
events, allergic reactions, weight change, hypoglycemia, and
insulin antibodies were similar between treatment groups. Si-
milar findings were observed in patients who were insulin-naı̈ve
or previously treated with IGlar at baseline.
Conclusions
Both LY IGlar and IGlar, when used in combination with
OADs, provided effective and similar glucose control with
similar safety profiles in patients with T2D.
Comment
As long-acting insulin analogues are widely used for
insulin therapy in patients with type 2 diabetes, it is clear
that also a clinical study in this patient group was per-
formed. The study results would have been easier to
interpret if two separate studies would have been per-
formed, one study with patients that were not on an
insulin-therapy previously (but on OADs) and one study
with patients with previous insulin therapy. However,
the data presented again showed that both insulin glar-
gines induce quite similar clinical outcomes.
Evaluation of immunogenicity of LY2963016 insulin
glargine compared with Lantus insulin glargine
in patients with type 1 or type 2 diabetes mellitus
Ilag LL1, Deeg MA1, Costigan T1, Hollander P 2,
Blevins TC 3, Edelman SV 4, Konrad RJ1, Ortmann RA1,
Pollom RK1, Huster WJ1, Zielonka JS1, Prince MJ1
1Eli Lilly and Company, Indianapolis, IN; 2Baylor Endocrine
Center, Dallas, TX; 3Texas Diabetes and Endocrinology, Aus-
tin, TX, 4University of California, San Diego, San Diego, CA
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Background
Aim of these studies was to compare the immunogenicity
profiles and the potential effects on clinical outcomes of
LY2963016 insulin glargine (LY IGlar) and the origina-
tor insulin glargine (IGlar) in patients with type 1 or type 2
diabetes mellitus (T1DM or T2DM).
Methods
Anti-insulin glargine antibodies (measured as percent
binding) were compared between treatments in 52 week
(open-label) and 24 week (double-blind) randomized stud-
ies in patients with T1DM (n = 535) and T2DM (n = 756),
respectively. In patients with type 2 two subgroups were
studied: insulin-naı̈ve patients and those reporting prestudy
IGlar treatment (prior IGlar). Relationships between insulin
antibody levels and clinical outcomes were assessed using
analysis of covariance and partial correlations. Treatment
comparisons for treatment-emergent antibody response (TEAR)
and incidence of detectable antibodies were analyzed using
Fisher’s exact test.
Results
No significant differences were observed for insulin anti-
body levels, incidence of detectable anti-insulin glargine
antibodies, or incidence of TEAR in patients with T1DM or
patients with T2DM, including the insulin-naı̈ve subgroup.
A significant difference was noted in the overall incidence
of detectable antibodies but not at endpoint nor in TEAR for
the prior IGlar subgroup of patients with T2DM. Insulin
antibody levels were low ( < 5%) in both treatment groups.
Insulin antibody levels or TEAR was not associated with
clinical outcomes.
Conclusions
Both glargine have similar immunogenicity profiles. Anti-
insulin glargine antibody levels were low with both glargine,
with no observed effect on efficacy and safety outcomes.
Comment
As stated above, the immunogenicity of BioIns is a
major concern and therefore the evaluation of the anti-
body formation in the two ELEMENT studies is of high
interest. At least under such study conditions both insulin
glargines do not differ in stimulation of the immuno-
logical response. The question remains, if this holds true
for all patients, it might be that small patient groups act
differentially and that this is not seen when analyzing
all patients as one group. Depending on the quality of the
pharmacovigilance system that is in place in the given
country, an increase in antibody titers to a level that
clinically relevant differences in insulin doses etc. show
up in such patients will be detected or not. Without a
structured and systematic evaluation (including mea-
surement of antibody titers), such patients will not be
detected in daily life. The question is who is willing to
pay for such an approach?
Efficacy and safety of LY2963016 insulin glargine
in patients with type 1 and type 2 diabetes
previously treated with insulin glargine
Hadjiyianni I1, Dahl D 2, Lacaya LB 3, Pollom RK 3,
Chang CL 3,4, Ilag LL 3
1Lilly Deutschland GmbH, Bad Homburg, Germany; 2Ge-
meinschaftspraxis für Innere Medizin und Diabetologie,
Hamburg, Germany; 3Eli Lilly and Company, Indianapolis,
IN; 4Ditmanson Medical Foundation Chiayi Christian Hos-
pital, Chiayi City, Taiwan
Diabetes Obes Metab 2016; 18: 425–429
Background and Methods
The safety and efficacy of LY2963016 insulin glargine
(LY IGlar) and originator insulin glargine (IGlar) were as-
sessed in subgroups of patients with type 1 (T1D, n = 452) or
type 2 diabetes (T2D, n = 299) that used IGlar prior to their
participation in a 52 week open-label study (ELEMENT-1) or
a 24 week double-blind study (ELEMENT-2). At randomi-
zation, patients were switched from their prestudy IGlar to
equivalent doses of LY IGlar or IGlar. Primary efficacy
(change in HbA1c from baseline to 24 weeks), other efficacy
and select safety outcomes of LY IGlar were compared with
those of IGlar.
Results
No statistically significant treatment differences were
identified for efficacy and safety outcomes except for
weight change (T1D), overall incidence of detectable in-
sulin antibodies (T2D), and serious adverse events (T2D).
These differences were neither consistently observed
across both studies nor observed in the total study popu-
lations, and their magnitude suggests they were not clini-
cally meaningful.
Conclusions
LY IGlar and IGlar show similar efficacy and safety pro-
files in patients using IGlar prior to study participation.
Comment
This additional analysis of patients with prestudy
IGlar treatment who were randomized to biosimilar
insulin glargine treatment showed no differences in
efficacy and safety outcomes to those of patients re-
ceiving IGlar during the study. The difference in
weight gain observed with LY IGlar is worth a follow-
up evaluation in daily practice. Also the significant
difference in overall antibody incidence of LY IGlar-
treated patients with T2D; this might be due to an
imbalance in baseline antibody levels. It is worth ac-
knowledging that neither study was designed to pro-
spectively compare LY IGlar and IGlar in patients
with diabetes reporting prestudy IGlar treatment. The




The next BioIns that most probably will come to the
market in the European Union and the United States is
another insulin glargine currently under development by
Merck-US. Merck has not published any data until now;
however, data presented at the American Diabetes Associa-
tion (ADA) in 2015 and 2016 document the similarity of this
BioIns with the originator insulin. Also other insulin glar-
gines are in clinical development (one by Biocon is in late
phases of the development) and also a BioIns of insulin lispro
(developed by Sanofi).
Prices
Market introduction of BioIns has not induced drastic
changes in the insulin market until now; however, once more
BioIns enter the market the increase in competition will most
probably change this. We will have to see if the prices start a
race to the bottom as it took place with test strips for blood
glucose measurement systems in the last years. This will also
depend on the pressure put behind a lowering of insulin prices
by insurance companies and/or the health-care system in the
given countries. It is of interest to note that prices for origi-
nator insulins—which have gone up especially in the United
States massively in the last years—are not driven up by the
manufacturer companies, but also by the pharmacy benefit
managers (7,8).
Clinical Experience
One can assume that in the near future the first reports
about the clinical experience of patients with diabetes will be
presented that have used the BioIns of insulin glargine in
daily practice; hopefully the manufacturer will present data
from their pharmacovigilance systems also.
Immunological Aspects
Market approval of BioIns means that these insulins have
similar pharmacokinetic and pharmacodynamic properties in
comparison to the originator insulins. During the approval
process also the preclinical data are evaluated carefully (see
the extended documentation of the EMA for Abasaglar);
however, a matter of concern is the question if BioIns might
differ in their immunogenic properties from the originator
insulin. Also this is studied during the approval process, a
clinical study with a limited number of subjects (300) over a
limited period of time (6 or 12 months) has to be performed.
The question remains if with such a study all relevant patient
groups are studied for a sufficient period of time. A major
concern is that at least in some patient’s formation of (neu-
tralizing) insulin antibodies is stimulated. Differences in
immunological responses might be induced by certain dif-
ferences between the BioIns and the originator insulin (9).
Quality
In the same line of thinking it would be of interest to know
how good the quality of different batches of (originator) in-
sulins and BioIns is over time. Insulin is manufactured in
batches and these might differ considerably from each other
as a reflection of the complexity of the manufacturing pro-
cess. The amount of information that companies are reporting
about this topic is quite limited (10–12).
Interchangeability
Switching from one insulin to another is a decision made
by the treating physician to exchange one insulin with an-
other insulin with the same therapeutic intent in a given
patient (13,14). Interchangeability means the practice of
changing one insulin for another that is expected to achieve
the same blood glucose lowering effect in any patient with
diabetes on the initiative or with the agreement of the phy-
sician. This requires that the insulin can be regarded as in-
terchangeable, i.e., as a property of a given insulin. In
contrast, substitution is a process in which, at the pharmacy
level, without (!) consulting the prescribing physician an-
other insulin (a BioIns) is dispensed instead of the prescribed
insulin. Currently there is no ‘‘substitutability determina-
tion’’ in the European Union, i.e., there is no automatic
substitution in practice in the European Union whereby a
pharmacist is obliged to dispense a BioIns instead of a pre-
scribed insulin. Interesting differences exists between states
in the United States when it comes to guidelines for mar-
ket allowance of BioIns (12).
Devices
In daily practice for patients, diabetologists, and nurses the
devices (most often insulin pens) used for application of in-
sulin are of high relevance. Each manufacturer of BioIns
comes to the market with a combination of their insulin glar-
gine with an insulin pen. The switch from the pen(s) of the
originator insulin to another one is associated with an addi-
tional teaching and training burden for the diabetes team. Such
aspects are of high relevance from a practical point of view.
Clinical Trials
A number of original articles reporting data from clinical
trials with BioIns were published in the last year, mainly data
from the clinical studies performed for approval of Abasaglar
were reported (15–19). However, also some comments and
reviews were published about BioIns, mainly directed towards
the usability of long glucose clamps for evaluation of the
pharmacodynamic (PD) properties of basal insulins (20,21)
and specific aspects like costs and interchangeability (8,13,22).
Summary
These are early days for BioIns. It can be taken for granted
that this story will gain more attention and momentum in the
next years. This will be mainly driven by cost aspects. Lower
insulin prices mean also that more patients can afford to buy
insulin or has access to it (23).
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MEANINGFUL BENEFIT OF A NEW DRUG CLASS
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Aim
Compared with human insulin, insulin analogues reduce
the risk of hypoglycemia in patients with type 1 diabetes
(T1D) and minor hypoglycemia problems. The HypoAna
trial has illustrated that for patients with recurrent severe
hypoglycemia, the risk of severe hypoglycemia is reduced
when treatment based on insulin analogues is employed. The
present study aims to assess whether this also applies to
nonsevere hypoglycemia events at night and during the day.
Methods
This investigator-initiated multicenter, prospective, ran-
domized, open, blinded endpoint (PROBE) trial that took
place over 2 years, involved participants with T1D who had
had at least two episodes of severe hypoglycaemia during the
previous year. These patients were randomized to basal-bolus
therapy based on analogue (detemir/aspart) or human (NPH/
regular) insulins using and balanced crossover design. In total
114 patients were included. Endpoints were the number of
both nonsevere and severe hypoglycemic events, including
documented symptomatic and asymptomatic episodes oc-
curring during the day and at night.
Results
A 6% overall relative-risk reduction for nonsevere hy-
poglycemia resulted from analogue-based treatment (2%–
10%; P = 0.0025). This was a result of a 39% (32%–46%;
P < 0.0001) reduction of nonsevere nocturnal hypoglycemia,
which was observed for both symptomatic (48% [36%–
57%]; P < 0.0001) and asymptomatic (28% [14%–39%];
P = 0.0004) nocturnal hypoglycemia episodes. There were no
clinically significant differences in hypoglycemia occurrence
observed between the insulin regimens during the day. To
avoid one episode (TNT1) of nonsevere nocturnal hypogly-
cemia, the time needed to treat one patient with insulin an-
alogues was approximately three months.
Conclusion
In T1D patients prone to severe hypoglycemia, treatment
with analogue insulin reduced the risk of nonsevere nocturnal
hypoglycemia compared with human insulin.
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Background
As reflected in a number of scientific debates, the use of
short-acting insulin analogue for people with diabetes re-
mains controversial.
Objectives
The aim of this study was to assess the effects of short-
acting insulin analogues versus regular human insulin in
adults with type 1 diabetes.
Search Methods
Electronic searches were carried out through Ovid
searching the following databases simultaneously: Ovid
MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946
to 14 April 2015), the Cochrane Central Register of Controlled
Trials (CENTRAL; March 2015), Ovid MEDLINE(R) In-
Process & Other Non-Indexed Citations, EMBASE (1988
to 2015, week 15), ClinicalTrials.gov and the European
(EU) Clinical Trials register (both March 2015), Ovid
MEDLINE(R).
Selection Criteria
All randomized controlled trials with an intervention du-
ration of at least 24 weeks and that compared regular human
insulins with short-acting insulin analogues in the treat-
ment of adults with type 1 diabetes who were not pregnant
were included.
Data Collection and Analysis
Independently, two review authors assessed trials and ex-
tracted data for risk of bias, and differences were resolved
by consensus. We graded the overall study quality using the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) instrument. Random-effects models
were used for the main analyses and the results presented
as odds ratios (OR) with 95% confidence intervals (CI) for
dichotomous outcomes.
Main Results
Nine trials that fulfilled the inclusion criteria, includ-
ing 2693 participants, were identified. Intervention duration
ranged from 24 to 52 weeks, with a mean of approximately 37
weeks. Participants exhibited some diversity, mainly with
regard to diabetes duration and inclusion/exclusion criteria.
Most of the trials were performed in the 1990s and partici-
pants were recruited from Europe, North America, Africa,
and Asia. None of the trials was carried out in a blinded
manner so that the risk of performance bias, especially
for subjective outcomes such as hypoglycemia, was present
in all of the trials. Several of the trials exhibited incon-
sistencies in the reporting of results and methods. The
mean difference (MD) in glycosylated hemoglobin A1c
(HbA1c) was - 0.15% (95% CI - 0.2% to - 0.1%; P value
< 0.00001; 2608 participants; 9 trials; low-quality evidence)
in favor of insulin analogues. Comparison of the risk of
severe hypoglycemia between the two treatment groups
demonstrated an OR of 0.89 (95% CI 0.71 to 1.12; P value =
0.31; 2459 participants; 7 trials; very low quality evidence).
For overall hypoglycemia, also taking into account mild
forms of hypoglycemia, most of the data were of a low
quality, but also did not indicate substantial group differ-
ences. In relation to nocturnal severe hypoglycemic epi-
sodes, two trials reported statistically significant effects in
favor of the insulin analogue, insulin aspart. However, in-
consistent reporting in publications and trial reports means
that the validity of the result are questionable. There was
also no clear evidence for a substantial effect of insulin
analogues on health-related quality of life. However, there
were few results only based on subgroups of the trial pop-
ulations. In none of the trials were substantial effects re-
garding weight gain or any other adverse events reported.
None of the trials were designed to investigate possible
long-term effects (such as all-cause mortality, diabetic
complications), in particular in people with diabetes-related
complications.
Conclusions
Our analysis suggests that there is only a minor benefit of
short-acting insulin analogues on blood glucose control in
people with type 1 diabetes. To draw conclusions regarding
the effect of short-acting insulin analogues on long-term
patient-relevant outcomes, long-term efficacy and safety data
are needed.
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Background
Technosphere insulin (TI), which is an inhaled human
insulin with a fast-action onset, provides a novel option for
the control of prandial glucose. The University of Virginia
(UVA)/Padua simulator was used in order to investigate,
in silico, the potential benefit of different dosing regimens on
postprandial glucose (PPG) control with the aim of support-
ing the design of further clinical trials. Tested dosing regi-
mens included at-meal or post meal dosing, or dosing before
and after a meal (split dosing).
Methods
We compared various dosing regimens of TI to each other
and to insulin lispro in 100 virtual type 1 patients. For each
regimen, individual doses were identified following different
titration rules. The postprandial glucose profiles that resulted
were analyzed to quantify efficacy and to assess the risk for
hypoglycemic events.
Results
The approach allowed us to compare results with simula-
tions of insulin lispro and to assess the benefit/risk for each TI
dosing regimen. We identified a new titration rule for TI that
could significantly improve the efficacy of treatment with TI.
Conclusion
Clinical trials, in silico, which compared the effect of
treatment with different dosing regimens with TI and of in-
sulin lispro suggest that splitting or post meal dosing of TI,
together with an appropriate titration rule, can achieve better
postprandial glucose control while at the same time yielding a
lower risk for hypoglycemic events than that achievable with
conventional treatment with subcutaneously administered
rapid-acting insulin products.
Comment
Learnings of two decades of experience with rapid-
acting insulin analogs show how difficult it is to scien-
tifically prove meaningful clinical benefits despite general
acceptance of the pharmacokinetic advantages of the
rapid-acting analogs. The Danish HypoAna trial con-
firmed the benefit of these drugs in high-risk patients
for severe hypoglycemia. The time needed to treat one
patient with insulin analogues to avoid one episode of
nonsevere nocturnal hypoglycemia was approximately
three months. Also the most recent analysis of the Co-
chrane group suggests only a minor benefit of short-
acting insulin analogues on blood glucose control mainly
because of criticisms of study design and data quality.
Possibly in silico approaches will be able to guide the
assessment of future new drugs, both in terms of the
development of new trials as well as characterizing pa-
tient subgroups that are likely to profit most from such a
drug. Regarding the efficacy of inhaled technosphere
insulin (Afrezza) such in silico testing has demonstrated
that post meal dosing or split dosing might be the best
approach. In light of the reimbursement discussion and
criticisms of study design and proof of efficacy with
current trial earlier use in silico studies may help to
better design studies and save resources and time. For
technosphere insulin this may be too late as it still is
lacking impact on clinical practice in spite of regulatory
approval.
Already last year we reported on the first published
data on faster aspart (24). This new formulation with
two well-known additional excipients, L-arginine and
niacinamide, provides a stable formulation with faster
initial absorption after subcutaneous administration. As
it is not an entirely new drug entity this may help both
regulatory approval and reimbursement scenarios. Both
excipients appear on the U.S. Food and Drug Adminis-
tration list of approved inactive ingredients, in prod-
ucts for injection that makes additional safety concerns
unlikely (25). The Onset program is a phase 3 clinical
program with faster-acting insulin aspart that consists of
several trials encompassing more than 2100 people with
type 1 and type 2 diabetes. First results were presented at
the 2016 Scientific Sessions of the American Diabetes
Association. The Onset 1 trial (1143 people randomized)
is a 26 + 26 week randomized, partially double-blind,
basal-bolus, treat-to-target trial investigating faster-
acting insulin aspart dosed at mealtime or 20 minutes
after starting a meal compared with NovoLog dosed at
mealtime, both in combination with a basal insulin in
adults with type 1 diabetes. Only the data from the first
26 weeks were reported at the 76th Annual Scientific
Sessions of the ADA in New Orleans. The primary
endpoint was change from baseline HbA1c versus
NovoLog, and a secondary endpoint was change from
baseline in 2 hour PPG increment versus NovoLog. In
Onset 1, after 26 weeks of randomized therapy, faster-
acting insulin aspart showed statistically significantly
greater HbA1c reduction versus NovoLog in adults with
type 1 diabetes when dosed at mealtime ([95% confi-
dence interval (CI)] - 0.15 [ - 0.23; - 0.07]). Faster-
acting insulin aspart also showed comparable HbA1c
reduction when dosed 20 minutes after starting a meal,
compared with NovoLog dosed at mealtime ([95%
CI] 0.04 [ - 0.04; 0.12]). Trial results for Onset 1 also
showed superior reduction in 2 hour PPG incre-
ment ([95% CI] - 0.67 [ - 1.29; - 0.04] mmol/L) versus
NovoLog. The change in 1 hour PPG increment, a
secondary supportive endpoint, was also reduced ([95%
CI] - 1.18 [ - 1.65; - 0.71] mmol/L) (26).
The Onset 2 trial (689 people randomized): a 26 week
randomized, double-blind, basal-bolus, treat-to-target
trial investigating faster-acting insulin aspart compared
with NovoLog, both dosed at mealtime and in combi-
nation with a basal insulin and metformin in adults
with type 2 diabetes. The primary endpoint was change
from baseline HbA1c versus NovoLog, and a secondary
endpoint was change from baseline in 2 hour PPG
increment versus NovoLog. In Onset 2, faster-acting
insulin aspart demonstrated noninferiority in HbA1c
reduction compared with NovoLog ([95% CI] - 0.02
[ - 0.15; 0.10]) in adults with type 2 diabetes. Trial
results could not confirm a statistically significant reduc-
tion in 2 hour PPG increment ([95% CI] - 0.36 [ - 0.81;
0.08] mmol/L). However, a statistically significant reduc-
tion in 1 hour PPG increment was shown with faster-acting
insulin aspart ([95% CI] - 0.59 [ - 1.09; - 0.09] mmol/L)
(2) that was a secondary supportive endpoint (27).
At the same meeting the first outpatient 14-day study
comparing the effect of multiple daily injections of
BioChaperone Lispro and Humalog (insulin lispro
rDNA origin) on postprandial glycemic control relative
to solid standardized meals in 36 patients with type 1
diabetes was presented. The study also investigated the
effects of different timing of administration, with
treatments being injected either at mealtime, 15 minutes
before, or 15 minutes after the start of a solid meal.
Whereas commercialized fast-acting insulin analogs are
usually injected before the meal, an ultra-rapid insulin
aims to allow injection at the time of the meal, or even
after the start of a meal, while maintaining a reduction in
the magnitude of glycemic excursions. In this double-
blind, randomized, crossover study, 36 patients with type
1 diabetes used individualized doses of either BioCha-
perone Lispro or Humalog as the short-acting insulin in
their multiple daily injection regimen, over two periods
of 14 days. At the beginning and the end of each period,
patients were subject to a meal tolerance test in the clinic
to compare postprandial blood glucose profiles after
identical bolus injections immediately before the meal
of either BioChaperone Lispro or Humalog relative to a
solid standard meal. At the beginning of the study, when
injected at the time of meal, BioChaperone Lispro
demonstrated a statistically significant 31 percent re-
duction in blood glucose excursion over the first two
hours compared to Humalog. After 14 days of treatment
for each treatment, BioChaperone Lispro also demon-
strated a statistically significant 42% reduction in blood
glucose excursion over the first two hours compared to
Humalog, when injected at the time of the meal (28).
It is likely that ultra-fast-acting insulin aspart will
be the first of the class to be commercially available
as NovoNordisk announced the submission to FDA and
EMEA late in 2015. Overall, it is likely that these ultra-
rapid-acting insulins will be able show their greatest benefit
in continuous subcutaneous insulin infusion (CSII) or even
closed-loop insulin therapy (29). In conclusion, the pipeline
of new insulins and insulin therapy promises to remain
interesting in the near future.
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